Assoc. Prof. Dr. Nargız Majıdova

Образование и специализация

2009–2015: Медицинское образование, медицинский факультет Университета Ондокуз Майыс, Самсун.

2016–2020: Ординатура по внутренним болезням, Университет Ондокуз Майыс, Самсун.

2021–2024: Субспециализация по медицинской онкологии, Университет Мармара, Стамбул.

Профессиональный опыт

2016–2020: Клиника внутренних болезней, Университет Ондокуз Майыс, Самсун.

2020–2021: Врач-терапевт, VM Medical Park Samsun.

2021–2024: Клиника медицинской онкологии, Университет Мармара, Стамбул.

2024–2026: Медицинский онколог, больница Maltepe Medical Park.

2026: Онкологическая больница Medical Park İstanbul.

Основные направления

Рак молочной железы

Рак легкого

Колоректальный рак

Рак желудка и поджелудочной железы

Рак простаты, почек и гинекологические опухоли

Членство в профессиональных обществах

Турецкое общество медицинской онкологии

Европейское общество медицинской онкологии (ESMO)

Американское общество клинической онкологии (ASCO)

Турецкая медицинская ассоциация

Исследования и публикации

Majidova N, Demirağ G, Pehlivanlar Küçük M. Akciğer kanserinde nadir görülen yaygın cilt metastazı. Tuberk Toraks. 2018 Sep 29;66(3):249–52.

Majidova N, et al. Gustave Roussy Immune Score (GRIm-Score) Predicts Prognosis in Non-Small Cell Lung Cancer Patients Undergoing Nivolumab: A Multicenter Retrospective Study from Turkiye. International Journal of Hematology and Oncology. 2024 Dec 30;34(4):206–12.

Majidova N, Simsek F, Biter S, Yaslikaya S, et al. Prognostic Factors Associated with Resected Osteosarcoma: Efficacy of Adjuvant Setting, Real-World Experience. UHOD- Uluslararasi Hematoloji-Onkoloji Dergisi. 2024;34(1):20–7.

Majidova N, Seyyar M, Güren AK, Kocaaslan E, Kırcalı MF, et al. Lung Immune Prognostic Index (LIPI): Prognostic predictor for patients with extensive-stage small-cell lung cancer. Marmara Medical Journal. 2025 Jan 29;38(1):24–8.

Majidova N, Sarı M, Kahvecioglu FA, Ozcan E, et al. Clinicopathologic Features and Efficacy of Induction Chemotherapy in Nasopharyngeal Carcinoma: Real-World Experience. Oncol Res Treat. 2024;47(7–8):360–7.

Majidova N, Arak H, Ozalp FR, Bas O, Koker GO, et al. Prognostic factors and outcomes of adjuvant and first-line metastatic treatments in melanoma a Turkish oncology group study. Sci Rep. 2025 Jan 25;15(1):3200.

Majidova N, Aghamaliyeva S, Guliyev M, Dinc G, et al. Sorafenib vs chemotherapy in the treatment of locally advanced or metastatic, radioactive iodine-refractory differentiated thyroid cancer: real-world data from Turkey. Journal of Chemotherapy. 2024 Nov 26;1–6.

Majidova N, Seyyar M, Bayraktar DI, Dinç G, İsgandarov E, Huseynov J, et al. Which factors help to determine the long-term response to first-line tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma: A Turkish multi-centre study. Biomolecules and Biomedicine. 2024 Oct 17;24(6):1776–84.

Majıdova N, Kırcalı Mf, Güren Ak, et al. Systemic Inflammation Response Index and Pan-Immune- Inflammation Value: Prognostic Significance in Metastatic Melanoma. Journal of Oncological Sciences. 2024;10(3):144–9.

Majidova N, Güren AK, Dinç G, Kırcalı MF, et al. Prognostic value of systemic inflammatory markers in renal cell carcinoma with isolated lung metastases: A retrospective analysis. Turkish Journal of Clinics and Laboratory. 2024 Dec 31;15(4):528–33.

Majidova N, Demirag G. An evaluation of the clinical and treatment features of renal cell carcinoma. Journal of Experimental and Clinical Medicine (Turkey). 2024;41(2):294–8.

KOSTEK O, Majidova N, et al. Long-Term Survival and Disease-Free Rates in Locoregional Anal Squamous Cell Carcinoma: An Institutional Experience. International Journal of Hematology and Oncology. 2024 Dec 30;34(4):213–9.

ARIKAN R, SAĞIROĞLU ÜSTÜN H, Majidova N, et al. Prognostic Significance of Mucinous Histology in Metastatic Colorectal Cancer Patients Treated with Regorafenib. Journal of Oncological Sciences. 2023;9(2):53–61.

Şimşek F, Majidova N, et all The Prognostic Importance of Clinicopathological Factorsin Patients with Osteosarcoma Who Received NeoadjuvantTherapy; A Single Center Experience; EJMI 2024;8(3):184–192

Sever N, Yunusov E, Majidova N, et al. Sex-related disparities in outcomes of survival in biliary tract cancer patients. J Cancer Res Clin Oncol. 2025;151(2):95. doi:10.1007/s00432-025-06096-y.

AKDAĞ G, ALAN Ö, Majidova N, et al. Efficacy and Safety of Ixabepilone in Metastatic Breast Cancer After Multiple Treatments: Analysis Based on Real-World Data. Journal of Oncological Sciences. 2024;10(2):89–96.

Sezgin Y, Karhan O, Aldemir MN, Ürün M, Erçek BM, Urakcı Z, Arvas H, Tunç S, Erdem M, Yerlikaya H, İleri S, Aydın İ, Bicer A, Kömürcüoğlu AU, Majidova N, et al. Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. Sci Rep. 2025;15(1):11675. doi:10.1038/s41598-025-96157-6. Correction: 2026, doi:10.1038/s41598-026-47335-7.

Sever N, Majidova N, et al. Baseline Demographic and Clinicopathologic Characteristics Affecting Treatment Efficacy in Metastatic NSCLC. Eurasian Journal of Medical Investigation. 2024;157–63.

Güren AK, Çakır İ, Majidova N, Kocaaslan E, Erel P, et al. Oncological perspective on Kaposi sarcoma: A single-centre experience. Marmara Medical Journal. 2025 Jan 29;38(1):9–14.

Kuzan BN, Majidova N, Ilgın C, Arslan H, Kursun M, Ozguven S, et al. Evaluation of sarcopenia-associated survival in breast cancer with computed tomography-based pectoral muscle area measurements. Marmara Medical Journal. 2024 May 31;37(2):178–84.

Kaan Güren A, Majidova N, Çakır İ, Sever N, Kocaaslan E, Erel P, et al. Efficacy of Combined Bevacizumab and Angiotensin-Converting Enzyme Inhibitors or Angiotensin II type 1 Receptor Blockers in Metastatic Colorectal Cancer Patients.

Telli TA, Bugdayci O, Alan O, Sariyar N, Majidova N, et al. Impact of Skeletal Muscle Measurements by Chest Computed Tomography on Survival and Postoperative Complications in Patients with Soft Tissue Sarcoma. Nutr Cancer. 2022 Aug 9;74(7):2499–507.

Güren AK, Kocaaslan E, Ağyol Y, Majidova N, Sever N, Erel P, et al. HER2 exon 20 mutant non-small cell lung cancer with complete remission of intracranial metastases with trastuzumab deruxtecan: a case report. Anticancer Drugs. 2024 Sep;35(8):769–73.

Yildirim HC, Bayram E, Chalabiyev E, Majidova N, et al. Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma. Journal of Chemotherapy. 2024 Sep 10;1–12.

Güren AK, Guliyev M, Alan Ö, Majidova N, et al. Evaluation of Dose Reduction Factors and Impact on Progression-Free Survival in Patients Treated with CDK 4/6 Inhibitors. J Clin Med. 2025 Feb 7;14(4):1071.

Bayoğlu İV, Hüseynov J, Topal A, Sever N, Majidova N, et al. PNI as a Potential Add-On Biomarker to Improve the IMDC Intermediate Prognostic Score. J Clin Med. 2023 Oct 9;12(19):6420.

Köstek O, Demirel A, Hacıoğlu MB, Majidova N, et al. The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencing. Journal of Chemotherapy. 2024 Oct 2;36(7):613–21.

Şenocak Taşçı E, Mutlu AU, Majidova N, et al. Total Neoadjuvant Therapy Versus Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: A Multi-Institutional Real-World Study. Cancers (Basel). 2024 Sep 21;16(18):3213.

Tünbekici S, Yuksel H cagatay, Acar C, Majidova N, et al. Regorafenib Treatment for Recurrent Glioblastoma Beyond Bevacizumab-Based Therapy: A Large, Multicenter, Real-Life Study. Cancers (Basel). 2024 Dec 27;17(1):46.

Guliyev M, Şen GA, Gültürk İ, Majidova N, Akdağ G, et al. The effects of low HER2 expression on survival in patients with metastatic breast cancer treated with CDK 4/6 inhibitors: a multicenter retrospective study. Breast Cancer Res Treat. 2024 Jun 25;205(3):633–40.

Tunbekici S, Yuksel HC, Acar C, Sahin G, Majidova N, et al. Efficacy and Safety of the Topotecan–Cyclophosphamide Regimen in Adult Metastatic Ewing Sarcoma: A Large, Multicenter, Real-World Study. Cancers (Basel). 2025 Feb 6;17(3):550.

Arıkan R, Alkış H, Işık S, Yaşar A, Çelebi A, Majidova N, et al. Evaluation of Predictive and Prognostic Importance of Lung Immune Prognostic Index in Locally Advanced Rectal Cancer Patients Treated With Neoadjuvant Chemoradiotherapy. Cureus. 2023 Jun 17;

Guliyev M, Güren AK, Özge E, Çolak R, Majidova N, et al. The Impact of Progesterone Receptor Status on Survival Outcomes in Metastatic Breast Cancer Patients Treated with First-Line CDK4/6 Inhibitors. Cancers (Basel). 2025 Feb 18;17(4):693.

Akyildiz A, Gultekin M, Yigit E, Majidova N, et al. Efficacy of cumulative cisplatin dose on survival in patients with locally advanced cervical cancer treated with definitive chemoradiotherapy: multicenter study by Turkish Oncology Group. International Journal of Gynecological Cancer. 2024 Sep;34(9):1359–65.

Sekmek S, Ozsan Çelebi SN, Majidova N, et al. Bevacizumab versus aflibercept with FOLFIRI after FOLFOX and bevacizumab in RAS mutant metastatic colon cancer a Turkish oncology group study. Sci Rep. 2024 Nov 30;14(1):29785.

Taşçı EŞ, Kutlu Y, Ölmez ÖF, Majidova N, et al. Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study. Expert Opin Pharmacother. 2024 Mar 3;25(4):477–84.

Akyildiz A, Guven DC, Koksal B, Majidova N, et al. Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG). European Archives of Oto-Rhino-Laryngology. 2024 Sep 25;281(9):4991–9.

Yildirim HC, Kapar C, Koksal B, Majidova N, et al. Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study. Journal of Chemotherapy. 2025 Jan 2;37(1):69–75.

Ozsay O, Karabacak U, Cetin S, Majidova N Is Diabetes Onset at Advanced Age a Sign of Pancreatic Cancer? Annali Italiani Di Chirurgia, 2022 93, 4: 476-480

Книги и главы в книгах

Majidova N (2023). Yaşlılarda kolorektal kanserde adjuvan tedavi. B. Akagündüz, B. Karabulut (Ed.), Kolorektal Kanserler. İstanbul: İstanbul Tıp Kitapevi.

Majidova N (2024). Kanser Hastalarının Başvurduğu Geleneksel ve Tamamlayıcı Tedaviler-Tıbbi Onkolog Gözü ile Bakış ve Onkolojik İlaçlarla Etkileşim. İstanbul Akademisyen Yayınevi

Устные научные доклады

Nargiz Majidova, Bahaddin Yılmaz, Arif Cengiz Gültekin. Bilateral testicular metastasis of prostate adenocarcinoma: A case report – 6th Congress of the Mediterranean Multidisciplinary Oncology Forum and 3rd İnternational Congress on Oncological Sciences 28 November-1 December 2019, Antalya (Oral presentation)

Abdussamet Çelebi, Alper Yaşar, Nadiye Sever, Nargiz Majidova, Rukiye Arıkan, Selver Işık, Murat Sarı, Özlem Ercelep, İbrahim Vedat Bayoğlu, Osman Köstek. The relationship between c-erbB2 positivity and disease-free survival in operated non-metastatic gastric cancer. 33rd congress of International Association of Surgeons, Gastroenterologists and Oncologists, 28 September- 1 October 2022, İstanbul (Oral presentation)

Javid Huseynov, Alper Yaşar, Abdussamet Çelebi, Nargiz Majidova, Nadiye Sever, Rukiye Arıkan, Selver Işık, Tuğba Akın Telli, Murat Sarı, Özlem Ercelep, İbrahim Vedat Bayoğlu, Osman Köstek. Evaluation of factors influencing on progression- free survival and overall survival of patients requesting first series tyrosin kinase inhibitör for metastatic renal cell carcinoma. İnternational Eurasıan uro-oncology congress; 1-4 september 2022, Erzurum (Oral presentation)

Hilal Sağıroğlu Üstün, Abdussamet Çelebi, Ibrahim Vedat Bayoğlu, Rukiye Arıkan, Alper Yaşar, Nargiz Majidova, Nadiye Sever, Murat Sarı, Selver Işık, Özlem Ercelep, Osman Köstek. What is the ideal sequence for regorafenib in the treatment of metastatic colorectal cancer? 12th İnternational gastrointestinal cancer conference, 1-4 december 2022, İstanbul (Oral presentation)

Nargiz Majidova, Güzin Demirağ, Mehtap Pehlivan. Küçük Akciğer kanserinde nadir görülen yaygın cilt metastazı- 13. Klinik Onkolojide Güncel Tedaviler Sempozyumu 4-6 Mayıs 2018, İzmir. (Oral presentation)

Nargiz Majidova, Güzin Demirağ. Sunitinib tedavisi alan metastatik böbrek hücreli karsinom hastalarımızın klinik olarak değerlendirilmesi- 2.Ulusal Ürogenital Kanserler Kongresi 11-14 Ekim 2018, Antalya (Oral presentation)

Tuğba Akın Telli, Selver Işık, Rukiye Arıkan, Abdussamet Çelebi, Alper Yaşar, Nargiz Majidova, Osman Köstek, Özlem Ercelep, İbrahim Vedat Bayoğlu. Erken evre extremite yumuşak doku sarkomlarında sağ kalım ile ilişkili prognostik faktörlerin değerlendirilmesi: Tek merkez deneyimi; 5.Ulusal immunoterapi ve onkoloji kongresi13-17 Ekim 2021 Antalya (Oral presentation)

Nargiz Majidova, Rukiye Arıkan, Alper Yaşar, Abdussamet Çelebi, Nadiye Sever, Selver Işık, Tuğba Akın Telli. Dosetaksel tedavisi ile ilişkili palmoplanter eritrodistezi sendromu: El sırtı tutulumu ön planda olan olgu sunumu ile – 2.Ulusal meme kanseri sempozyumu, 4-6 Şubat 2022, İstanbul (Oral presentation)

Nargiz Majidova, Rukiye Arıkan, Alper Yaşar, Abdussamet Çelebi, Nadiye Sever, Selver Işık, Tuğba Akın Telli Küçük hücreli dışı akciğer kanserinde osimertinib tedavisi;olgu sunumu nedeniyle. 5.Gençlerle onkolojiye bakış kongresi; 4-6 Mart 2022, online (Oral presentation)

Alper Yaşar, Rukiye Arıkan, Abdussamet Çelebi, Nargiz Majidova, Nadiye Sever, Selver Işık, Tuğba Akın Telli Adjuvan tedavi ile izlenen erkek meme kanserli hastada gelişen metastatik evre hastalık, olgu sunumu. 5.Gençlerle onkolojiye bakış kongresi; 4-6 Mart 2022, online (Oral presentation)

Nadiye Sever, Rukiye Arıkan, Alper Yaşar, Abdussamet Çelebi, Nargiz Majidova, Selver Işık, Tuğba Akın Telli Yaygın metastatik meme kanserinde ribosiklib tedavisine erken yanıt — 5.Gençlerle onkolojiye bakış kongresi; 4-6 Mart 2022, online (Oral presentation)

Nargiz Majidova, Abdussamet Çelebi, Selver Işık, Murat Sarı, Osman Köstek. Metastatik Malign Melanomda Temel klinik özellikler ve prognostik faktörler. Uğur Yılmaz Onkoloji Günleri, Nadir Tümörler Sempozyumu; 25-27 Şubat 2022; İzmir (Oral presentation)

Nadiye Sever, Rukiye Arıkan, Alper Yaşar, Abdussamet Çelebi, Nargiz Majidova, Selver Işık, Tuğba Akın Telli. Beyin Metastazlı MSI-H endometriyum kanser olgusu. Uğur Yılmaz Onkoloji Günleri, 9. Nadir Tümörler Sempozyumu; 25-27 Şubat 2022; (Oral presentation)

Nargiz Majidova, Abdussamet Çelebi, Selver Işık, Osman Köstek, İbrahim Vedat Bayoğlu Triple negatif meme kanserinde klinikopatolojik özellikler ve tedavi yanıtı; tek merkez deneyimi 6.Karadeniz meme kongresi, 9-11 Mart 2023, Samsun (Oral presentation)

Nargiz Majidova, Alper Yaşar, Abdussamet Çelebi, Nadiye Sever, Selver Işık, Özlem Ercelep, Murat Sarı, Osman Köstek, İbrahim Vedat Bayoğlu İnvaziv lobüler meme kanserinde klinikopatolojik özellikler ve tedavi yanıtı; tek merkez deneyimi 3.Meme kanseri Sempozyumu, 17-19 Şubat 2023, Kıbrıs (Oral presentation)

Nargiz Majidova, Emil Yunusov, Abdussamet Çelebi, Selver Işık, Dilek Gül, Osman Köstek, Beste Atasoy Nazofarenks kanserinde klinikopatolojik özellikler ve tedavi yanıtı; tek merkez deneyimi 10.Nadir Tümörler Sempozyumu, 24-26 Şubat 2023, İzmir (Oral presentation)

Nargiz Majidova, Murat Sarı İnvaziv mesane kanserinde klinikopatolojik özellikler ve tedavi yanıtını etkileyen prognostik faktörler, tek merkez deneyimi AVOD onkoloji günleri, 17-19 Mart 2023, Eskişehir (Oral presentation)

Fatih Şimşek, Nargiz Majidova, Alper Yaşar, Selver Işık, Rukiye Arıkan, Osman Köstek Neoadjuvan tedavi almadan opere edilen ve adjuvan tedavi verilen osteosarkom hastalarında klinikopatolojik faktörlerin prognostik önemi: Tek merkez deneyimi 10.TTOK, 24-26 Nisan 2023, Antalya (Oral presentation)

Abdussamet Çelebi, Alper Yaşar, Nadiye Sever, Nargiz Majidova, Rukiye Arıkan, Osman Köstek, İbrahim Vedat Bayoğlu, Murat Sarı Metastatik baş boyun kanserlerinde platin bazlı kemoterapi ve setuksimab tedavisi etkinlik verileri: tek merkez deneyimi 8. Multidisipliner Baş boyun kanserleri kongresi, 20-21 Mart 2023, Antalya (Oral presentation)

Nargiz Majidova RAİ Refrakter ve Metastatik Diferansiye Tiroid Kanserinde Genel Sağkalımı Etkileyen Faktörler, Tek Merkez Deneyimi 1-3 Eylül abant onkoloji günleri Safranbolu (Oral presentation)

Nargiz Majidova, Güzin Demirağ Renal Hücreli Karsinom Hastalarının Klinik Ve Tedavi Özelliklerinin Değerlendirilmesi — 8. Karadeniz Onkoloji Günleri, 28-30 Eylül 2023, Trabzon (Oral presentation)